Skip to content
i2E
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Menu
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Search

Chinese company acquires Cytovance Biologics

Get in Touch

Chinese company acquires Oklahoma City firm Cytovance Biologics
By Paul Monies
Copyright © 2015 The Oklahoma Publishing Co.

Cytovance Biologics Inc., an Oklahoma City-based pharmaceutical contract manufacturer, will be acquired by a unit of a Chinese company in a $206 million deal, the companies announced Monday.

Hepalink USA, a subsidiary of Shenzhen Hepalink Pharmaceutical Co. Ltd., said the acquisition will allow it to accelerate Cytovance’s expansion plans.

“We are excited about this transaction and what it means for Cytovance,” Darren Head, president and CEO of Cytovance, said in a statement. “This will expand our ability to develop and grow both our domestic and international businesses and to secure our current expansion plans in our Oklahoma City facilities. We do not anticipate any changes in how we currently do business. We will become part of a very successful company that shares our commitment to safety and quality.”

Cytovance has 178 employees, all in Oklahoma City. The company’s management team will stay in place after the transaction closes.

“We welcome and are honored to have Hepalink as the new owner of Cytovance,” said Dr. William Canfield, co-chair and founder of Cytovance. “They will be thrilled, as I have been, to work with Cytovance’s extraordinarily talented and capable team of professionals who have made a practice of exceeding customer expectations while building one of the world’s best companies in the biopharmaceutical contract manufacturing market.”

Cytovance’s product lines are biologics, therapeutic proteins and antibodies made from either mammal cells or cells from bacteria. The company’s expansion plans include the addition of 5,000-liter and 10,000-liter mammalian reactors, which are used to grow proteins from mammal cells. It also expects to add 1,000-liter and 5,000-liter microbial fermentors, which are used to grow proteins from bacteria.

Cytovance products are used by researchers for clinical trials to help find better vaccines and cures for diseases such as cancer, sickle cell anemia, asthma and gout.

Hepalink said the addition of Cytovance will strengthen its contract development and manufacturing organization portfolio, which also includes Wisconsin-based Scientific Protein Laboratories LLC.

“Hepalink will accelerate the realization of its strategy in the global macromolecule biopharmaceutical space,” Li Li, Hepalink’s chairman and CEO, said in a statement. “Cytovance will have the resources to expand its manufacturing capabilities, enhancing its ability in late-stage clinical drug production and commercial business. We are very impressed with Cytovance’s top-tier leadership team and will entrust this team to lead the future growth of the company.”

Under the terms of the deal, Hepalink will acquire Cytovance for $205.68 million in cash, plus certain contingent payments. The transaction is expected to close in October following regulatory approval.

Read the story at NewsOK.com

Author

  • admin admin

More News

Loading...
woman in lab conducting a study
Blog, i2E
12.13.22

Bayesic Technologies Improves Effectiveness and Efficiency of Data Analysis in Healthcare

Read more
Bison grazing fields
Blog
11.30.22

Bison Underground Merges Nature, Science, and Technology to Tackle Climate Change

Read more
African American family sitting on couch reading and chatting
Blog, E3, i2E
11.22.22

Fokes Connects Families, Caregivers and Care Agencies for Smoother Communications and Care 

Read more
i2e blog post graphic
Blog, News
11.03.22

Introducing: Stories of Oklahoma Innovation

Read more
Default Featured Image
OKBio
06.28.22

Oklahoma Grown! i2E Invests in BIO startups

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma Medical Research Foundation BIO

Read more
Default Featured Image
OKBio
06.13.22

Moleculera Labs BIO

Read more
Default Featured Image
OKBio
06.13.22

University of Oklahoma Health Sciences Center BIO

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma State University BIO

Read more
Default Featured Image
OKBio
06.13.22

ECHO Investment Capital BIO

Read more
Default Featured Image
OKBio
06.13.22

AscendBioVentures BIO

Read more
Default Featured Image
OKBio
06.13.22

Dean McGee Eye Institute BIO

Read more
i2E

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
+1 (405) 235.2305

Tulsa Office

100 S. Cincinnati Ave – Suite 514
Tulsa, OK 74103
+1 (918) 582.5592

  • Client Portfolio
  • About Us
  • Media
  • Events
  • Contact
  • Resources

© 2022 i2E Privacy Policy

Follow us:

Facebook Twitter Linkedin

Programs

  • E3
  • ACT Tulsa
  • Love's Entrepreneur's Cup
  • OKBio
  • Client Portfolio

Services

  • Access to Funding
  • Venture Advisory Services
  • Contact
  • About
  • Our Values
  • Our Team
  • Board of Directors
  • Corporate Partners
  • Media
i2E